Covered recipient · General Payments record
SCOTT A FRETZIN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$90,783.84
206 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $70,488.50 | 38 |
| Consulting Fee | $8,160.00 | 5 |
| Honoraria | $6,000.00 | 3 |
| Food and Beverage | $3,362.97 | 151 |
| Travel and Lodging | $2,765.41 | 8 |
| Education | $6.96 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $21,762.71 | 50 |
| Janssen Scientific Affairs, LLC | $15,884.97 | 11 |
| Lilly USA, LLC | $13,413.28 | 22 |
| Amgen Inc. | $13,264.78 | 27 |
| UCB, Inc. | $11,810.08 | 12 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $6,195.21 | 7 |
| Incyte Corporation | $5,364.97 | 7 |
| E.R. Squibb & Sons, L.L.C. | $1,250.00 | 1 |
| Almirall LLC | $800.00 | 1 |
| Novartis Pharmaceuticals Corporation | $388.75 | 29 |
| PFIZER INC. | $157.57 | 9 |
| Genentech USA, Inc. | $115.50 | 1 |
| Janssen Biotech, Inc. | $110.64 | 16 |
| GENZYME CORPORATION | $101.59 | 6 |
| Regeneron Healthcare Solutions, Inc. | $97.21 | 4 |
| STRATA Skin Sciences, Inc. | $39.99 | 1 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $13.99 | 1 |
| LEO Pharma Inc. | $12.60 | 1 |
Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SCOTT A FRETZIN
NPI 1023011244 · CMS profile ID 91643
Allopathic & Osteopathic Physicians / Dermatology
INDIANAPOLIS, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023011244?year=2021&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SCOTT A FRETZIN, NPI 1023011244, CMS profile ID 91643. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023011244?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). SCOTT A FRETZIN, NPI 1023011244, CMS profile ID 91643. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023011244?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- SCOTT A FRETZIN, NPI 1023011244, CMS profile ID 91643, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–206 of 206 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1023011244?year=2021&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
206 matching records · $90,783.84 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–206 of 206.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $17.09 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794515933 | CMS |
| UCB, Inc. | $12.30 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807294615 | CMS |
| Lilly USA, LLC | $15.05 | 01/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818679857 | CMS |
| Novartis Pharmaceuticals Corporation | $3.12 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812682737 | CMS |
| UCB, Inc. | $1,600.00 | 01/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807292141 | CMS |
| GENZYME CORPORATION | $14.50 | 01/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843499717 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,638.02 | 8 |
| PY2025 | Principal investigator | $1,302,291.15 | 229 |
| PY2024 | Recipient | $114.46 | 1 |
| PY2024 | Principal investigator | $1,170,043.67 | 187 |
| PY2023 | Recipient | $4,895.67 | 2 |
| PY2023 | Principal investigator | $830,146.44 | 133 |
| PY2022 | Recipient | $194.00 | 1 |
| PY2022 | Principal investigator | $1,120,785.72 | 168 |
| PY2021 | Principal investigator | $1,483,673.50 | 196 |
| PY2020 | Recipient | $3,573.00 | 4 |
| PY2020 | Principal investigator | $1,365,446.43 | 248 |
| PY2019 | Recipient | $32,006.00 | 3 |
| PY2019 | Principal investigator | $1,747,506.82 | 173 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
237 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $3,537.36 | 12/31/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202534141 |
| Principal investigator 1 | PFIZER INC. | $11,035.00 | 12/31/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 MULTICENTER LONGTERM OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO PEDIATRIC PARTICIPANTS AGED 2 YEARS AND OLDER WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228738482 |
| Principal investigator 1 | PFIZER INC. | $2,408.27 | 12/31/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228745037 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 12/31/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 | No dispute reported | 06/30/2026 | 1228747936 |
| Principal investigator 1 | PFIZER INC. | $13,809.00 | 12/31/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB PF06651600 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1228750370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,726.00 | 12/29/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175305794 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.24 | 12/18/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220799145 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.92 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679160 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $163.24 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679162 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679164 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,241.00 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679166 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.60 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679168 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $305.90 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679170 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679172 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679174 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679176 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679178 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.62 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679180 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.76 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679182 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $258.06 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679184 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $41.50 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679186 |
| Principal investigator 1 | PFIZER INC. | $1,876.50 | 12/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228723886 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 12/16/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228745064 |
| Principal investigator 1 | PFIZER INC. | $1,114.76 | 12/11/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228732247 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,377.00 | 12/08/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113774 |
| Principal investigator 1 | ABBVIE INC. | $4,482.00 | 12/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202526702 |
| Principal investigator 1 | ABBVIE INC. | $5,833.50 | 12/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202526704 |
| Principal investigator 1 | ABBVIE INC. | $10,634.25 | 12/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202526706 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,511.00 | 12/01/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | VELARITE | No dispute reported | 06/30/2026 | 1211595724 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,658.00 | 12/01/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | VELARITE | No dispute reported | 06/30/2026 | 1211595729 |
| Principal investigator 1 | PFIZER INC. | $4,462.43 | 11/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228729574 |
| Principal investigator 1 | PFIZER INC. | $2,408.27 | 11/25/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228729412 |
| Principal investigator 1 | PFIZER INC. | $4,814.75 | 11/25/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228737694 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.88 | 11/19/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679158 |
| Principal investigator 1 | ABBVIE INC. | $16,346.25 | 11/05/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522791 |
| Principal investigator 1 | ABBVIE INC. | $20,361.60 | 11/05/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202522793 |
| Principal investigator 1 | ABBVIE INC. | $3,463.50 | 11/05/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202522859 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $510.60 | 11/05/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226113791 |
| Principal investigator 1 | ABBVIE INC. | $6,201.60 | 11/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202521023 |
| Principal investigator 1 | ABBVIE INC. | $14,451.75 | 11/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202521025 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,371.00 | 11/03/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | VELARITE | No dispute reported | 06/30/2026 | 1211595716 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,981.00 | 11/03/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | VELARITE | No dispute reported | 06/30/2026 | 1211595720 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,246.00 | 11/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175305801 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,857.00 | 10/20/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113719 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,397.60 | 10/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226113782 |
| Principal investigator 1 | Eli Lilly and Company | $1,083.00 | 10/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187878713 |
| Principal investigator 1 | ABBVIE INC. | $2,571.95 | 10/09/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202513901 |
| Principal investigator 1 | ABBVIE INC. | $28,536.30 | 10/09/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202513903 |
| Principal investigator 1 | PFIZER INC. | $1,233.63 | 10/09/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228741580 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,220.80 | 10/08/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220791510 |
| Principal investigator 1 | PFIZER INC. | $4,069.42 | 10/03/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228722858 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,853.00 | 09/29/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU P LLC | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175305749 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 09/25/2025 | Non-covered Recipient Entity Dawes Fretzin Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175216988 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.66 | 09/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679152 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 09/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679154 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 09/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679156 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 09/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220791508 |
| Principal investigator 1 | PFIZER INC. | $1,098.63 | 09/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228750508 |
| Principal investigator 1 | PFIZER INC. | $10,240.00 | 09/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A LONGTERM DOUBLEBLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031 | No dispute reported | 06/30/2026 | 1228770443 |
| Principal investigator 1 | ABBVIE INC. | $3,321.00 | 09/09/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202510324 |
| Principal investigator 1 | PFIZER INC. | $13,640.00 | 09/09/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228757496 |
| Principal investigator 1 | ABBVIE INC. | $10,162.20 | 09/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202507637 |
| Principal investigator 1 | ABBVIE INC. | $1,458.50 | 09/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202507639 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,179.00 | 09/03/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113715 |
| Principal investigator 1 | PFIZER INC. | $1,661.15 | 08/30/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228766623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,371.00 | 08/29/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU P LLC | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175305740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.80 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679136 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $87.40 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679142 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.92 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679148 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.00 | 08/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679150 |
| Principal investigator 1 | PFIZER INC. | $2,095.07 | 08/20/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228767570 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,856.30 | 08/20/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226113735 |
| Principal investigator 1 | Janssen Research & Development, LLC | $670.00 | 08/19/2025 | Non-covered Recipient Entity Dawes Fretzin Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175216878 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,978.00 | 08/19/2025 | Non-covered Recipient Entity Dawes Fretzin Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175217240 |
| Principal investigator 1 | PFIZER INC. | $4,620.00 | 08/14/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228787438 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,998.00 | 08/08/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU P LLC | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175305785 |
| Principal investigator 1 | ABBVIE INC. | $3,668.00 | 08/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202502949 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,480.30 | 08/06/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226113731 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,024.65 | 08/06/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226113746 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,500.00 | 08/06/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226113758 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,250.00 | 08/06/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226113764 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 08/06/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226113771 |
| Principal investigator 1 | ABBVIE INC. | $1,458.50 | 08/05/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202501616 |
| Principal investigator 1 | PFIZER INC. | $2,694.74 | 08/05/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228767102 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,668.00 | 08/04/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226113685 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,904.00 | 08/04/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113688 |
| Principal investigator 1 | PFIZER INC. | $10,040.00 | 08/02/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228785701 |
| Principal investigator 1 | Eli Lilly and Company | $31,644.00 | 07/28/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187879713 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $7,793.00 | 07/25/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | VELARITE | No dispute reported | 06/30/2026 | 1211595699 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,700.00 | 07/25/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | VELARITE | No dispute reported | 06/30/2026 | 1211595704 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $200.00 | 07/25/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | VELARITE | No dispute reported | 06/30/2026 | 1211595708 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $750.00 | 07/25/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | VELARITE | No dispute reported | 06/30/2026 | 1211595712 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,004.00 | 07/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220791506 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,700.00 | 07/23/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220791500 |
| Principal investigator 1 | Eli Lilly and Company | $3,083.11 | 07/17/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187879789 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,235.00 | 07/14/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113676 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,500.00 | 07/14/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113680 |
| Principal investigator 1 | PFIZER INC. | $2,026.89 | 07/11/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228787110 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,492.00 | 07/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU P LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175305757 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 07/09/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226113751 |
| Principal investigator 1 | ABBVIE INC. | $1,799.25 | 07/08/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497468 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,000.00 | 07/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234515136 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,000.00 | 07/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234515139 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $199.00 | 07/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234515152 |
| Principal investigator 1 | ABBVIE INC. | $8,423.85 | 07/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202496491 |
| Principal investigator 1 | ABBVIE INC. | $9,721.20 | 07/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202496493 |
| Principal investigator 1 | ABBVIE INC. | $2,165.50 | 07/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202496589 |
| Principal investigator 1 | ABBVIE INC. | $13,226.10 | 07/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202496591 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,518.60 | 07/02/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226113667 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,131.80 | 07/02/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226113741 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,345.00 | 06/30/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU P LLC | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175305772 |
| Principal investigator 1 | UCB SA | $2,145.00 | 06/30/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF TWO DOSES OF BIMEKIZUMAB IN ADOLESCENT STUDY PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1246657834 |
| Principal investigator 1 | PFIZER INC. | $3,447.37 | 06/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228776218 |
| Principal investigator 1 | PFIZER INC. | $1,328.51 | 06/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228778147 |
| Principal investigator 1 | PFIZER INC. | $11,235.00 | 06/26/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 | No dispute reported | 06/30/2026 | 1228786895 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $36,213.75 | 06/11/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226113706 |
| Principal investigator 1 | ABBVIE INC. | $1,360.50 | 06/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202487333 |
| Principal investigator 1 | ABBVIE INC. | $2,201.30 | 06/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202487441 |
| Principal investigator 1 | ABBVIE INC. | $1,990.00 | 06/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202488227 |
| Principal investigator 1 | ABBVIE INC. | $3,994.05 | 06/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202489577 |
| Principal investigator 1 | ABBVIE INC. | $7,738.65 | 06/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202489679 |
| Principal investigator 1 | ABBVIE INC. | $5,243.10 | 06/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202489785 |
| Principal investigator 1 | Eli Lilly and Company | $13,649.95 | 06/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187878711 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,391.00 | 06/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU P LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175305733 |
| Principal investigator 1 | PFIZER INC. | $2,695.00 | 05/30/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228764508 |
| Principal investigator 1 | ABBVIE INC. | $1,592.00 | 05/29/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202487039 |
| Principal investigator 1 | PFIZER INC. | $1,596.11 | 05/29/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228764412 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 05/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679122 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.20 | 05/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.55 | 05/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679126 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $70.38 | 05/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.50 | 05/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679130 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,118.10 | 05/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226113660 |
| Principal investigator 1 | ABBVIE INC. | $18,629.84 | 05/15/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202485163 |
| Principal investigator 1 | PFIZER INC. | $2,989.66 | 05/14/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228772743 |
| Principal investigator 1 | ABBVIE INC. | $1,799.25 | 05/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202483753 |
| Principal investigator 1 | ABBVIE INC. | $1,794.55 | 05/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202483755 |
| Principal investigator 1 | ABBVIE INC. | $1,875.25 | 05/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202483757 |
| Principal investigator 1 | ABBVIE INC. | $1,421.25 | 05/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202483759 |
| Principal investigator 1 | ABBVIE INC. | $6,097.05 | 05/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202483887 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,494.00 | 05/07/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220791504 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $440.40 | 05/07/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226113700 |
| Principal investigator 1 | ABBVIE INC. | $1,448.25 | 05/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202482143 |
| Principal investigator 1 | PFIZER INC. | $2,577.82 | 05/06/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228722770 |
| Principal investigator 1 | PFIZER INC. | $5,648.56 | 05/06/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228764501 |
| Principal investigator 1 | Incyte Corporation | $3,993.06 | 04/24/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240522673 |
| Principal investigator 1 | Eli Lilly and Company | $6,714.77 | 04/23/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187879711 |
| Principal investigator 1 | Eli Lilly and Company | $6,915.00 | 04/22/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187880699 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.11 | 04/15/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220799143 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,690.65 | 04/14/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226113640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,900.00 | 04/11/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU P LLC | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175305766 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,585.25 | 04/11/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226113693 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $20,108.60 | 04/10/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) | No dispute reported | 06/30/2026 | 1235997760 |
| Principal investigator 1 | Eli Lilly and Company | $21,747.10 | 04/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187880753 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,626.75 | 04/09/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, Llc | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis | No dispute reported | 06/30/2026 | 1235997758 |
| Principal investigator 1 | PFIZER INC. | $1,596.11 | 04/08/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228797888 |
| Principal investigator 1 | ABBVIE INC. | $5,868.90 | 04/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202468800 |
| Principal investigator 1 | ABBVIE INC. | $1,956.25 | 04/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202468805 |
| Principal investigator 1 | ABBVIE INC. | $526.00 | 04/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202468809 |
| Principal investigator 1 | ABBVIE INC. | $8,061.00 | 04/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202468813 |
| Principal investigator 1 | ABBVIE INC. | $3,531.00 | 04/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202468822 |
| Principal investigator 1 | ABBVIE INC. | $1,215.30 | 04/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202473950 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,754.00 | 03/31/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCHGROU P LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175305780 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,864.45 | 03/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226113637 |
| Principal investigator 1 | UCB SA | $46,191.00 | 03/21/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENTS FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1246656310 |
| Principal investigator 1 | PFIZER INC. | $1,131.83 | 03/14/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228789307 |
| Principal investigator 1 | ABBVIE INC. | $8,267.60 | 03/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202459289 |
| Principal investigator 1 | ABBVIE INC. | $1,360.50 | 03/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202459293 |
| Principal investigator 1 | ABBVIE INC. | $2,613.30 | 03/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202459298 |
| Principal investigator 1 | ABBVIE INC. | $5,006.25 | 03/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202460293 |
| Principal investigator 1 | ABBVIE INC. | $3,624.20 | 03/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202460743 |
| Principal investigator 1 | ABBVIE INC. | $1,299.75 | 03/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202456521 |
| Principal investigator 1 | Incyte Corporation | $825.66 | 03/05/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240522669 |
| Principal investigator 1 | ABBVIE INC. | $3,030.60 | 03/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202455575 |
| Principal investigator 1 | PFIZER INC. | $1,249.31 | 03/04/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228781149 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,021.00 | 03/03/2025 | Non-covered Recipient Entity Dawes Fretzin Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175216955 |
| Principal investigator 1 | PFIZER INC. | $3,781.09 | 02/28/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228758719 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,745.55 | 02/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226113629 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $56.00 | 02/21/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117597 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,386.00 | 02/18/2025 | Non-covered Recipient Entity Dawes Fretzin Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175216928 |
| Principal investigator 1 | PFIZER INC. | $8,950.00 | 02/11/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228757463 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $325.47 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117585 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $446.00 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117587 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $68.89 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117589 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $30.01 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117591 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $96.17 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117593 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $62.01 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117595 |
| Principal investigator 1 | ABBVIE INC. | $1,630.50 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202446858 |
| Principal investigator 1 | ABBVIE INC. | $11,271.00 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202447382 |
| Principal investigator 1 | ABBVIE INC. | $1,423.40 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202447387 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202447525 |
| Principal investigator 1 | Incyte Corporation | $370.32 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240522660 |
| Principal investigator 1 | PFIZER INC. | $1,563.80 | 02/06/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228759310 |
| Principal investigator 1 | ABBVIE INC. | $4,222.50 | 02/05/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202444447 |
| Principal investigator 1 | Amgen Inc. | $11,991.72 | 02/05/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP, LLC | A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis | No dispute reported | 06/30/2026 | 1246640655 |
| Principal investigator 1 | Eli Lilly and Company | $25,587.60 | 02/05/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187878709 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,265.25 | 02/04/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226113625 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,440.40 | 01/30/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679092 |
| Principal investigator 1 | Amgen Inc. | $21,099.65 | 01/27/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP, LLC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246640653 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.64 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679094 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679096 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $474.50 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679100 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.80 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679102 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $87.40 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679104 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.42 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679106 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.42 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679108 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.42 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679110 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.42 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679112 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.54 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679114 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.84 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679116 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $62.56 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679118 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.00 | 01/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220679120 |
| Principal investigator 1 | Eli Lilly and Company | $5,584.56 | 01/27/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187881254 |
| Principal investigator 1 | PFIZER INC. | $1,279.80 | 01/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228713820 |
| Principal investigator 1 | PFIZER INC. | $2,257.20 | 01/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228714014 |
| Principal investigator 1 | PFIZER INC. | $2,611.22 | 01/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228799726 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $610.60 | 01/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226113648 |
| Principal investigator 1 | Incyte Corporation | $3,289.87 | 01/23/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240522656 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 01/21/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202440364 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $553.47 | 01/21/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117583 |
| Principal investigator 1 | PFIZER INC. | $2,672.50 | 01/15/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group LLC | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228799375 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $769.50 | 01/15/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226113654 |
| Principal investigator 1 | ABBVIE INC. | $2,430.60 | 01/09/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202437349 |
| Principal investigator 1 | Eli Lilly and Company | $58,791.07 | 01/08/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1187877829 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,789.90 | 01/07/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220791502 |
| Principal investigator 1 | Eli Lilly and Company | $94,073.00 | 01/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187881332 |
| Principal investigator 1 | Incyte Corporation | $2,194.24 | 01/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240522664 |
| Principal investigator 1 | ABBVIE INC. | $2,829.00 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202433454 |
| Principal investigator 1 | ABBVIE INC. | $481.15 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202433485 |
| Principal investigator 1 | Amgen Inc. | $14,321.51 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP, LLC | P2 Moderate-Severe pDLE | No dispute reported | 06/30/2026 | 1246640657 |